List view / Grid view
What if familiar lab formats could be redesigned to remove the weak points in permeability and absorbance testing? This article explores how design choices in common consumables can improve both speed and reproducibility in early-stage research.
Bispecific T-cell engagers are advancing fast - but complexity still slows development. This article explores how data-driven, platform-based strategies are helping overcome design and manufacturing hurdles to bring these next-gen therapies to patients faster.
As radioligand therapy continues to show promise, its application in solid tumours remains limited by long-standing biological challenges. In this interview, Julien Torgue, CSO at Orano Med, discusses a new collaborative platform – Radio-DARPins – and how it could help overcome key barriers to clinical progress.
Researchers at the National University of Singapore have discovered that physically squeezing stem cells through narrow spaces can trigger their transformation into bone-forming cells – potentially allowing for development of new bone repair therapies.
A team of researchers have developed the first vascularised organoid model of human pancreatic islets, which could lead to further development of advanced cell therapies for diabetes.
Cell and gene therapy is rapidly transforming the treatment of complex diseases, yet scaling production efficiently remains a challenge. Dr Tia Harmon from PHC Corporation of North America explores the innovations that are optimising cell expansion to enhance the discovery of advanced therapies.
Cellenkos' CRANE technology, led by Dr Simrit Parmar, harnesses regulatory T cells to precisely target and treat inflammatory diseases. This innovative approach offers hope for conditions like aplastic anaemia, myelofibrosis, and ALS.
Tune in to this episode where we explore how innovative assays and human-relevant cell models are transforming toxicity screening in drug development.
The commercial production of recombinant proteins, such as antibodies and enzymes, relies on generating and maintaining specific cell lines designed to produce these specialised molecules. However, the creation of cell lines is a technically demanding and time-consuming process. For this reason, many businesses seek partnerships with contract development and manufacturing…
Dr Anis H Khimani from Revvity explores how key developments have enhanced biotherapeutic workflows, and explores how a transposon system can aid stable clone development.
3 January 2024 | By Eurofins DiscoverX
Watch this webinar to discover functional cell-based assays for characterizing novel therapeutics & biosimilars targeting cytokines in inflammation & oncology.
Listen to this podcast where we dive into genetic engineering, its role and relationship with allogeneic immunotherapy.
In this exclusive interview with Young Kwon, CEO of Alchemab, we discuss new platforms that are revolutionising how researchers identify naturally occurring antibodies in resilient individuals, opening up new possibilities for the development of disease-modifying therapies.
20 July 2023 | By Eurofins DiscoverX
Watch this webinar to discover qualified bioassays assessing therapeutic antibody mechanisms, case studies about agonistic effects in antibodies initially deemed antagonistic, and explore Fc receptor impacts on antibody response in co-culture assays.
Drug Target Review’s Taylor Mixides exclusively interviews Matt Angel, PhD, Chief Executive Officer and President of Eterna Therapeutics, about a potential new class of cell therapies that may play an important role in the development of new cancer treatments.
